INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA):IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Research Article

Factors Affecting Pharmaceutical Pricing In India

Syed Saif Imam*, Shiraz Mehdi

Department of Hospital Management and Hospice Studies Jamia Millia Islamia

ARTICLE INFO

Received: 17 May 2024
Accepted: 21 May 2024
Published: 26 May 2024

Keywords:
Pharmaceutical pricing, Drug price order, 5C framework, Indian pharmaceutical industry, pricing policy management

DOI:
10.5281/zenodo.11314004

ABSTRACT

The National Pharmaceutical Pricing Authority (NPPA) and the Drug Price Control Order (DPCO) provide distinct regulatory frameworks that the pharmaceutical business in India, which is widely recognized for its size and intricacy, operates in. The study employs the 5C paradigm, which consists of Compliance, Competition, Cost, Consumer, and Consequences, to examine the complex interactions among variables that impact pharmaceutical price decisions. Drug costs are mostly controlled by the regulatory framework, which is anchored by the DPCO. The NPPA is in charge of keeping an eye on compliance and enforcing pricing restrictions. There is ongoing discussion on these measures' efficacy in guaranteeing affordability and promoting innovation. The differentiation between necessary and non-essential pharmaceuticals, in addition to the variations in cost between generic and branded drugs, contributes to the complexity of the pricing environment. This article investigates the competitive environment of the Indian pharmaceutical sector and how it affects pricing tactics by looking at market dynamics. The intricacy of pricing dynamics is influenced by market concentration, entry obstacles, and the power of multinational firms. The practice of international price referencing and its influence on domestic pricing decisions are also covered, emphasizing how interrelated the pharmaceutical markets are on a worldwide scale. The socioeconomic consequences of pharmaceutical pricing are also examined, with a focus on how it affects healthcare affordability and accessibility. The difficulties in managing pricing policies are highlighted by differences in the availability of necessary medications among various socioeconomic groups.

INTRODUCTION

India's pharmaceutical sector has grown through an amazing journey marked by notable accomplishments and international acclaim. This introduction offers an overview of the main drivers behind the pharmaceutical industry's strong growth in India. It draws attention to India's rise to prominence in the world pharmaceutical market, which has been fueled by a number of advantages including a robust manufacturing sector, a sizable labor pool, and a welcoming regulatory framework [1,2]. The introduction also discusses how the

***Corresponding Author:** Syed Saif Imam
Address: *Department of Hospital Management and Hospice Studies Jamia Millia Islamia*
Email : saifbehappy@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

sector makes healthcare more accessible by producing affordable generic medications. The milestones, difficulties, and opportunities for the future that influence the dynamic pharmaceutical growth landscape in India will become clearer as we go deeper into this investigation. India's pharmaceutical market structure is distinguished by a dynamic and diverse terrain. This structure is made up of different parts, each of which is essential to the overall operation of the industry. India is renowned for having made a substantial contribution to the world market for generic medications. The manufacture and distribution of generic medications, which lower the cost and increase access to healthcare both domestically and abroad, dominate the pharmaceutical industry [3]. Pharmaceutical businesses that operate on a global scale coexist with domestic competitors in this market. Large international pharmaceutical corporations do business in India, but there are also many local businesses that provide a wide range of healthcare services. A key factor in forming the market is the regulatory environment, which is overseen by organizations such as the Central Drugs Standard Control Organization (CDSCO). Tight laws guarantee product efficacy, safety, and quality, building consumer confidence and promoting global cooperation. Many Indian pharmaceutical businesses are actively involved in medication discovery and innovation as the focus on research and development grows [4]. The goal of this move toward R&D is to solve new healthcare issues and improve the industry's competitiveness on a worldwide scale. India has a complicated distribution system that combines merchants, wholesalers, and e-commerce sites. Pharmacies are efficiently supplied throughout the nation thanks in part to this varied distribution strategy. By 2030, it is anticipated that the Indian pharmaceutical industry would have a total market value of US$ 130 billion. By FY25, the domestic pharmaceutical market is expected to grow to US$ 57 billion with operating margins expected to expand by 100–150 basis points (bps). Tata Memorial Centre of India and Vietnam National Cancer Hospital inked an agreement on December 21, 2020, to foster partnership in the fields of training and scientific research, health care services, and cancer patient diagnosis and treatment [5].

Market Structure of India:

India is the world's biggest supplier of generic pharmaceuticals and is renowned for its reasonably priced immunizations and generic meds. The pharmaceutical sector in India has grown over the previous nine years at a compound annual growth rate (CAGR) of 9.43%, placing it third in the world in terms of pharmaceutical output volume. Among the main sectors of the Indian pharmaceutical business are biologics, biosimilars, contract research & manufacturing, over-the-counter pharmaceuticals, bulk drugs, vaccines, and generics. The US Food and Drug Administration (USFDA)-compliant pharmaceutical manufacturing facilities are most numerous in India, which also boasts 500 API companies accounting for around 8% of the global API market [6]. India's pharmaceutical industry provides more than half of the world's demand for different vaccinations, 40% of the US market for generic drugs, and 25% of the UK market for all medications. Approximately 10,500 manufacturing facilities and 3,000 pharmaceutical businesses make up the domestic pharmaceutical industry. India holds a significant place in the world pharmaceutical industry. The nation is also home to a sizable population of scientists and engineers who might lead the sector to new heights [7]. Currently, Indian pharmaceutical companies supply more than 80% of the antiretroviral medications needed worldwide to treat AIDS (acquired immunodeficiency syndrome). India's reputation as the "pharmacy of the world" is well-earned given the reasonable prices and excellent

quality of its pharmaceuticals. Worldwide, the Indian pharmaceutical industry is renowned for producing affordable vaccinations and generic medications. Indian Pharma has evolved into a thriving industry over the years, currently ranking third in terms of volume of pharmaceuticals. India's pharmaceutical sector ranks third globally in terms of volume and fourteenth globally in terms of value. Currently, the pharmaceutical industry makes up 1.72 percent of the GDP of the nation. A recent EY FICCI analysis states that the Indian pharmaceutical market is expected to reach a valuation of US$ 130 billion by the end of 2030 due to the rising consensus around the provision of novel and inventive remedies to patients. In the meantime, it is predicted that the pharmaceutical industry would reach a valuation of over $1 trillion by 2023 [8].

Market Competition:

Competition takes many forms, including product innovation, market penetration, and pricing strategies, as local and international businesses compete for market share. Domestic pharmaceutical companies compete fiercely by utilizing cost advantages, scale, and in-depth knowledge of regional market dynamics. These companies are frequently known for their agility and adaptability. The global skills, research capacity, and brand recognition that multinational firms bring to the table heighten competition and stimulate innovation. Pricing methods are significantly shaped by this competitive frenzy, as businesses carefully place their products to obtain a competitive edge. In therapeutic categories with high demand and low entry barriers, price competition is especially strong, which puts pressure on prices and drives industry-wide attempts to optimize costs. In addition, the advents of online pharmacies and generic substitutes have increased competition, forcing businesses to adjust their pricing policies in order to stay in business [9]. Pricing decisions in this highly competitive environment are impacted not just by market forces but also by legislative restraints like price caps and government initiatives. As a result, the degree of rivalry among Indian pharmaceutical companies has a big impact on pricing tactics, which in turn drives innovation and cost savings and eventually shapes how accessible and affordable medications are for customers [10].

International Price Referencing:

International price referencing provides a framework for controlling pharmaceutical prices and fostering affordability; nevertheless, its implementation in the Indian context calls for close attention to stakeholder engagement, transparency, and contextual variables. In the future, policymakers will have to walk a tightrope between using global standards as a guide and customizing pricing to fit the particular requirements and circumstances of the Indian healthcare system. By doing this, India will be able to take advantage of the potential that worldwide medication price referencing offers in order to promote pharmaceutical innovation, increase patient outcomes, and improve healthcare access [11]. The practice of regulating pharmaceutical pricing in India by reference global drug prices has attracted a lot of attention and discussion in the fields of policy and healthcare. International price referencing (IPR) advocates contend that this approach ensures that consumers have access to reasonably priced medications and competitive pricing by comparing domestic drug costs to those of other nations. Nevertheless, detractors question the suitability and efficacy of this strategy in the Indian setting, pointing out differences in national regulatory frameworks, healthcare systems, and economic development. Fundamentally, intellectual property rights (IPR) entail evaluating medicine costs in India against a set of reference countries, which are usually wealthier nations with strong healthcare systems and greater purchasing power [12]. This practice's justification is to use

these reference countries' price negotiations and market dynamics to guide domestic pricing decisions. Policymakers seek to balance affordability with encouraging pharmaceutical innovation and investment by tying drug costs to global benchmarks. Nonetheless, there are a number of difficulties and ramifications with IPR application in India. First off, a key factor in determining the efficacy of IPR is the choice of reference nations. Opponents contend that the socioeconomic background and healthcare requirements of the Indian populace may not be adequately reflected in the current basket of reference countries. Furthermore, the inclusion of nations with noticeably greater income levels and healthcare spending may lead to inflated reference prices, which could result in prescription prices that are unaffordable for the people of India. Complicating the process of pricing comparison and benchmarking is the variation in healthcare systems and regulatory frameworks among reference nations. The efficacy of intellectual property rights (IPR) as a pricing tool can be undermined by variations in healthcare finance methods, reimbursement policies, and intellectual property regimes, which can skew price differentials. Moreover, policymakers face difficulties in precisely evaluating and enacting price modifications based on global benchmarks due to the opaqueness of international drug pricing data and the scarcity of trustworthy market information [13]. Beyond just pricing dynamics, IPR has wider ramifications for access to healthcare, affordability, and pharmaceutical innovation. Opponents contend that because lower price restrictions reduce possible revenue and return on investment, an over-reliance on IPR may discourage local pharmaceutical research and development. This could therefore make it more difficult to get novel medications and make headway in meeting India's unmet medical requirements [14].

Drug price control order (NPPA) Background:

In India, the National Pharmaceutical Pricing Authority (NPPA) is in charge of setting acceptable pricing for pharmaceuticals and guaranteeing their supply. The Ministry of Chemicals and Fertilizers' Department of Pharmaceuticals oversaw the establishment of the authority in 1997. Implementing and enforcing the government's Drug Price Control Orders (DPCO) is the main goal of the NPPA [15]. In 1970, the first Drug Price Control Order (DPCO) was issued, granting the government the authority to control the cost of prescription drugs. The order's main goals were to guarantee that medications were available to the general people and to stop their exorbitant cost. More medications were placed under price restriction when the DPCO was updated in 1987. More important medications are now included in the list of prohibited substances [16]. In 2012, the DPCO was updated to strengthen price control mechanisms. The updated directive established the idea of a National List of Essential Medicines (NLEM) and added new medications to the price control mechanism. The NPPA regulated the cost of medications included in the NLEM [17]. In order to make the regulation of medicine pricing stronger, the DPCO was further changed in 2019. The redesigned order contained clauses limiting the costs of non-scheduled formulations, which were previously exempt from direct price control. Additionally, a revised formula was used to determine the ceiling prices for both scheduled and non-scheduled formulations [18].

Analysis of DPCO and pricing policies of India and other Countries:

The pharmaceutical industry was estimated to be worth $1,135 billion globally in 2017. Over the past ten years, the market has grown steadily, and this tendency is expected to continue. An anticipated 3.1 percent growth rate for the European Union and 5.4 percent growth rate for North America is projected through 2022. The

global health economy, which includes the pharmaceutical sector, supported 183 million workers worldwide in 2014 and added 5,600 billion dollars to the global GDP [19]. The pharmaceutical sector contributes 8% of GDP to the global health economy, which means it has a significant influence on solving contemporary issues. Significant future effects are anticipated from the largely unexplored emerging markets. Due to their enormous growth potential, which is demonstrated by rising consumer income and the per capita usage of medication, it is anticipated that medical spending in these areas will expand at a rate of five to eight percent per year through 2023. As a result, the pharmaceutical sector has had and will continue to have a large economic impact on the world economy in terms of employment and GDP production [20]. In India, managing pricing policies entails taking into account variables like manufacturing costs, market demand, competition, and legal requirements. For the purpose of maintaining profitability and competitiveness, businesses frequently modify their pricing strategy based on these factors. Making educated decisions regarding pricing requires keeping up with market developments and economic realities. Furthermore, maintaining fair and clear pricing policies and adhering to legal requirements are critical components of long-term company operations [21,22]. With a total financial outlay of US$ 60.9 million (Rs. 500 crore), the Ministry's "Strengthening of Pharmaceutical Industry (SPI)" program provides the necessary support to MSMEs and established pharma clusters around the nation to increase their sustainability, productivity, and quality. By March 2025, the government hopes to have boosted the number of Pradhan Mantri Bhartiya Jan Aashaadha Kendra's to 10,500. PMBJP's product line includes 240 surgical equipment and 1,451 medications. The National Medical Devices Policy, 2023 was authorized by the Union Cabinet on April 26, 2023. This policy is anticipated to support the expansion of the medical device industry in order to achieve the public health goals of affordability, quality, innovation, and accessibility [23]. For greenfield pharmaceutical ventures, the automatic method has authorized up to 100% of FDI. FDI is permitted for brownfield pharmaceutical projects up to 74% automatically and up to that amount with government approval. Between April 2000 and March 2023, the drugs and pharmaceuticals industry received a total of US$ 21.46 billion in foreign direct investment (FDI) equity inflow. This amounts to nearly 3% of the total foreign direct investment received in all sectors. In the US and EU, Indian pharmaceutical businesses hold a sizable portion of the prescription market. India has the greatest number of FDA-approved plants outside of the United States [24].

Impact on Healthcare Access:

The rules of pharmaceutical pricing are crucial in determining the availability of important medicines to different socio-economic classes in India. These policies have a significant impact on healthcare affordability and equity since they are shaped by variables like market dynamics, regulatory frameworks, and healthcare infrastructure [25]. The availability of cheap treatment alternatives is a critical factor in determining the accessibility of crucial medicines for economically disadvantaged and marginalized communities. Prioritizing affordability in pricing strategies through the use of mechanisms like as price restrictions, generic replacement, and government subsidies are crucial to keeping essential medications affordable for these at-risk groups. For instance, a variety of essential medications from various therapeutic categories are included in India's National List of Essential Medicines (NLEM), which is governed by the Drug Price Control Order (DPCO) and has price controls [26,27]. The goal of the DPCO is to

increase low-income people and underprivileged communities' access to vital medicines by imposing price caps on them. Regardless, there are still difficulties in converting price rules into noticeable enhancements in accessibility, especially in isolated and rural regions with inadequate healthcare facilities. Accessibility impediments frequently prevent the provision of necessary medications at the community level. These include insufficient distribution networks, stockouts, and inequities in healthcare delivery. Furthermore, there may be differences in the effectiveness and quality of generic substitutes, which raises questions regarding patient safety and trust in less expensive treatment options [28]. On the other hand, though in different ways, price rules can also affect middle-class and upper-class individuals' access. Even while these groups might have more money to spend, they might still be negatively impacted financially by high prescription costs, especially when it comes to chronic and non-communicable illnesses. Price strategies that maintain access to necessary medications without jeopardizing the long-term viability of the pharmaceutical sector must find a balance between affordability and encouraging innovation. The difficulty, though, is balancing conflicting goals and interests, such as promoting research and development, generating income, and controlling costs [30]. Furthermore, price policies need to take into account the special requirements and vulnerabilities of certain patient groups, such as kids, the elderly, and people with long-term illnesses. Customized methods, such patient support programs and differential pricing schemes, might lessen access gaps and guarantee that necessary medications are distributed fairly across various socioeconomic groups. Pharmaceutical price policies have a big impact on how many various socioeconomic groups in India can afford necessary medications [31]. While affordability is still a key component of these policies, steps to increase access also need to be taken to strengthen the healthcare system, increase the effectiveness of the supply chain, and remove structural obstacles to healthcare delivery. India can endeavour to attain universal access to vital medications and promote health equity throughout the country by implementing a comprehensive strategy that takes into account the requirements and circumstances of heterogeneous patient groups.

Challenges and Potential solutions in regulating pharmaceutical pricing:

Effectively regulating pharmaceutical price is extremely difficult because of the intricate interactions between many variables, including market dynamics, legal frameworks, and healthcare goals. Even with initiatives to guarantee affordability and accessibility, legislators continue to face obstacles that prevent price regulations from operating as best they can. Given these obstacles, a number of viable fixes and areas for development become apparent in order to strengthen pharmaceutical pricing regulation going forward. Finding a balance between affordability and promoting innovation is one of the main issues in pharmaceutical pricing regulation [32]. Price caps and other governmental actions intended to drive down the cost of pharmaceuticals may unintentionally discourage R&D, impeding pharmaceutical innovation and the release of novel treatments. In order to tackle this issue, governments ought to investigate substitute pricing methods that incentivize inventiveness while guaranteeing patient affordability. By adjusting drug prices in accordance with their therapeutic benefit and financial impact, value-based pricing strategies, tiered pricing structures, and differential pricing models provide ways to balance these conflicting demands [33]. The absence of accountability and openness in pharmaceutical pricing procedures is another difficulty. The public's confidence in pricing rules is weakened by opaque pricing

negotiations, complicated pricing systems, and limited transparency into pricing techniques, which conceal the true cost of medications. Policymakers can require manufacturers to justify price hikes, mandate more disclosure of pricing data, and set up public inspection and accountability procedures in order to improve transparency. Regulators can enable consumers, healthcare providers, and legislators to make well-informed decisions and hold pharmaceutical corporations responsible for fair pricing practices by promoting openness and accountability. In addition, the worldwide expansion of pharmaceutical markets poses difficulties for international pricing regulation [34]. Global initiatives to harmonize pricing policies and benchmark drug costs are complicated by differences in economic development, healthcare systems, and regulatory frameworks among nations. Policymakers might investigate novel approaches to cross-border pricing coordination, create standardized standards for medication pricing data and methodology, and encourage increased international collaboration and information sharing in order to address this problem. Through the promotion of global collaboration, regulatory bodies can harness the combined knowledge and assets to create more just and efficient pricing policies that cut across national borders [35]. Additionally, it is difficult to modify pricing laws to satisfy the requirements of contemporary healthcare systems due to the changing nature of healthcare delivery and payment arrangements. Value-based reimbursement agreements, population health management programs, and value-based healthcare models all call for pricing strategies that balance cost-effectiveness with patient outcomes improvement. In order to tackle this issue, authorities should investigate novel pricing structures that encourage favourable health outcomes and value-based care delivery, such as outcome-based pricing agreements, subscription models, and risk-sharing arrangements [36]. Regulators may promote a more affordable and patient-centred healthcare ecosystem that emphasizes value by adopting these creative pricing strategies. Although there are several obstacles in the way of efficiently controlling pharmaceutical price, legislators have a number of viable options and opportunities for advancement at their disposal. The effectiveness and fairness of pharmaceutical pricing regulations can be improved by regulators through the adoption of innovative pricing models, international collaboration, and transparency. This will guarantee that patients have access to reasonably priced, high-quality medications that fulfil their healthcare requirements [37].

5C's framework analysis in pharmaceutical industries:

The pharmaceutical industry's 5Cs are a strategy framework that includes a number of elements essential to the long-term viability and performance of pharmaceutical businesses. Generally speaking, the 5Cs stand for Companies, Competitors, Context, Customers, and collaborators. Pharmaceutical firms can use the 5Cs framework as a strategic roadmap to help them navigate the ever-changing and complex industry landscape [38]. Pharmaceutical firms can improve their competitiveness, innovation, and overall performance in a demanding and rapidly changing market by concentrating on Companies, Competitors, Context, Customers, and collaborators initiatives. It's important to remember that different companies and industrial contexts may have different interpretations of and focus on each C's.



Fig 1: 5 C Analysis Frameworks

Companies:

Indian pharmaceutical companies are vital to meeting healthcare requirements, boosting economic growth, and competing in international pharmaceutical markets. These businesses play a wide range of complex and varied functions in marketing, distribution, manufacturing, R&D, and other areas. The pharmaceutical sector is made up of businesses that create, produce, sell, and distribute both name-brand and generic medications. Typically, corporations concentrate on creating either branded or generic medications due to the significant differences in their different business strategies. For instance, the generic medicine business model necessitates especially strong competency in manufacturing, channel management, and patent disputes, whereas the branded drug business model demands very large investments in R&D and marketing [39]. The pharmaceutical industry has had annual growth of approximately 10 percent, resulting in a total sales value of $602 billion in 2005. Of this amount, the top ten companies accounted for 45 percent (Forbes.com, 2006; IMS Health, 2006). Dollar sales are more heavily skewed toward branded medications and so better reflect prescription spending due to the difference in average price levels between branded and generic drugs, whereas unit sales more accurately reflect actual utilization [40].

R & D

The pharmaceutical industry's significant R&D expenses are a defining feature of product innovation. The process of introducing novel pharmaceuticals to the Indian market is extensive and encompasses several stages, such as research and development, clinical trials, regulatory clearances, and commercialization. It is estimated that the average economic cost of introducing a new medication into the Indian market is between $161 million and $4.5 billion [41]. However, it does highlight the reality that, despite pharmaceutical research potentially being more efficient than ever before due to improved techniques and technologies like high-throughput screening and logical drug design, bringing a new medication to market can still be very costly. The most widely accepted theory for this is that the low-hanging fruit has already been picked, and the recent decline in Food and Drug Administration (FDA) approvals of non-clinical equivalents (NCEs) would seem to corroborate this theory. Alongside these high research expenses are regulatory pressures to conduct progressively

larger and more costly clinical studies [42]. The high barrier to entry for new products in the pharmaceutical business affects the pricing dynamics that we see. First, R&D expenses act as a formidable barrier to entry, reducing the level of rivalry that businesses must contend with and enabling market leaders to maintain higher prices. Secondly, companies need to be able to anticipate substantial returns on their investment in innovation because research and development expenses are quite costly. It is commonly known that profitability and innovation go hand in hand. Governments use patents as a key instrument to try and address the innovation issues that occur when reduced expected returns make it less desirable to keep investing in R&D [43].

Product life cycle

Patents are a tool used by governments to offset the potential dynamic inefficiency brought on by high development costs. By giving companies that create new pharmaceutical items a brief window of market exclusivity, patents promote innovation. This determines the typical life cycle of pharmaceutical items, which, depending on how rapidly generic competitors join the market; can end within months of the patent expiring. The average effective patent life is 11.5 years, despite the fact that patents are active for 20 years from the date of filing since companies register patents prior to starting clinical trials (PhRMA, 2006). A patented molecule must contend with other unique molecules that have been approved to treat the same general ailment in order to avoid direct competition, which means that a patent does not provide monopolistic power [44]. There are several ways in which patent holders can try to prolong the patent life of their medications. If patents were staggered, for instance, so that the patent on the chemical expires at a different period than the patent on the production process or distribution system, generic entry might be delayed. Companies often get patent extensions for non-product-related reasons; two examples are the two-year extension Claritin acquired in an addition to the 1994 GATT treaty, or the fairly common six-month extension for filing a pediatric indication. A new version of an already-existing product may also be presented by well-known firms in the year before the patent expires [45]. As a result, rival companies must either take on greater risk of losing out on possible market share or suffer higher entry costs as they create generic copies of each formulation. Before their patents expire, patent holders may also release their authorized generic products, provide a license to a different generic producer, or lower the cost of their brand product [46].

Competitors:

The pharmaceutical sector in India is characterized by intense competition, since multiple companies operate across multiple segments such as over-the-counter (OTC) medications, active pharmaceutical ingredients (APIs), generic drugs, and biotechnology goods. The Indian pharmaceutical industry's dynamics are significantly shaped by its competitors. Their interactions and tactics have an impact on things like market share, pricing, innovation, and the general evolution of the sector. For a limited period of time—20 years in India, for example—patents shield pharmaceutical items from direct competition from same-molecule copycats. Nevertheless, since they do not stop rival producers from releasing unique compounds onto the market to cure the same ailment, patents cannot totally eliminate competition. When patents expire, generic producers are free to launch products that are essentially identical to the branded product. This increases competition, lowers the average cost of a molecule, and frequently leads to a market that is contracting as a result of manufacturers' reduced marketing support [47].

Branded Competition

In India, 87% of the pharmaceutical market is made up of branded generics, with generics making up the majority of the market. The prevalence of branded generics in India has an impact on generic competition and medicine pricing, according to a market analysis on the Indian pharmaceutical industry done by the Competition Commission of India (CCI). The survey also highlights the expansion of the generic medication market in India, the country that supplies the most generic drugs worldwide. Despite being secured by a patent, the market conditions that prescription drugs operate in are best characterized as an oligopoly, with multiple unique, patent-protected goods competing for market share within a therapeutic class. Being separate compounds, they could target patients with different risk factors or somewhat different symptoms, they might have various side-effect profiles, and they might operate through different chemical pathways, resulting in varying efficacy. Larger markets typically draw more entrants, although entry into a given therapeutic class is restricted due to the high entry costs associated with generating a unique medicinal molecule [48]. Depending on how much of a therapeutic benefit they offer over other medications in a therapeutic class, brand-name goods are frequently divided into two categories: innovative and "me-too" treatments. This distinction plays a major role in the explanation of drug launch prices. Pharmaceuticals that offer notable therapeutic benefits over currently available medications within a therapeutic class typically come with three times the price tag of other name-brand medications in that class. Conversely, "me-too" medications typically bring slight enhancements over current offerings, which mean they increase some pricing competitiveness in the market [49].

Generic Competition

The prevalence of branded generics in India has an impact on generic competition and medicine pricing, according to a market analysis on the Indian pharmaceutical industry done by the Competition Commission of India (CCI). The survey also highlights the expansion of the generic medication market in India, the country that supplies the most generic drugs worldwide. Legislators in India have determined that the best and most efficient way to lower prescription costs is through generic competition, according to an article published in The Better India. Less patents in India means greater generic competition, which benefits developing country citizens and governments by lowering the cost of medications [50]. Instead of attempting to compete with generic companies, brand name manufacturers concentrate on less elastic market niches once generic businesses enter the market. As a result, volume declines, but pharmaceutical companies can still boost prices to attract the remaining, less flexible clients. Now that most states have generic replacement legislation allowing pharmacists to fill prescriptions with generic medications when available, these segmentation-based pricing patterns are presumably less appealing. The majority of insured patients have plans that use formularies to incentivize switching to generic drugs by raising the co-payment for the branded version of a drug and decreasing the co-payment for the generic version, even in the absence of such rules [51]. When a patent expires, brand name manufacturers can choose to launch their generic products and take direct aim at generic copycats as an alternative to raising the price of their name brands. If the company can make more money during the generic exclusivity period than if they were to concentrate on the inelastic portion of the market, then this is a winning proposal because there would be no entry fees.

Customers:

The final users of pharmaceutical items are called customers. The market is directly impacted by their desire for pharmaceuticals. The demand for

particular pharmaceuticals is influenced by a number of factors, including an aging population, a rise in the prevalence of chronic diseases, and changing healthcare needs. Patients, insurance companies, and physicians share the roles of payer, end-user, and decision-maker in the pharmaceutical product market. So, in this section we are going to focus on the different roles of customers and payers and how they affect pricing of pharmaceuticals products [52].

End-users

The main concerns of patients and healthcare professionals are related to the safety, convenience, and efficacy of drugs. Factors such as side effects, convenience of usage, and treatment outcomes impact their decision-making. Pricing plans need to take the end-user's perception of the drug's value into account. Certain pharmaceuticals may have premium cost due to factors including brand loyalty, special therapeutic qualities, and patient benefits. In situations where out-of-pocket expenses are substantial, patient assistance programs, discounts, or co-pay help may be put into place to increase affordability for end users [53]. Pharmaceuticals that are seen to offer better clinical results or special advantages can be accepted by patients and medical experts, increasing demand and opening up new markets. Pricing policies ought to be in line with how much the patient believe the drug is worth. Premium pricing might be justified by differentiating with cutting-edge features or patient-friendly formulas.**Payers**

Payers, such as government health organizations and insurance firms, prioritize controlling healthcare costs while guaranteeing that patients have access to affordable treatments. They evaluate the entire economic value of pharmaceuticals when making decisions. Payers frequently bargain with pharmaceutical corporations to obtain rebates or reduced costs, particularly for medications that have therapeutic substitutes. When negotiating prices, the capacity to show value in the real world and cost-effectiveness becomes essential [54]. Drugs with lower costs or better overall value may be preferred or given priority by payers, therefore formulary placement is crucial for market access. Having your product listed in preferred formularies can increase sales. Drugs with a high cost-effectiveness, budget impact, or value for money may be given priority by payers. Providing data from the actual world and positive economic results can help open up new markets. In price negotiations with payers, proving clinical efficacy and cost-effectiveness are frequent requirements. It can be beneficial to offer tiered pricing structures, outcomes-based agreements, or value-based pricing. It is crucial to comprehend the different roles that payers and end users play in the pharmaceutical sector in order to create pricing strategies that work. A well-rounded strategy that takes into account the clinical and financial worth of the product is essential for commercial success and for reaching a large patient base. Pharmaceutical businesses need to manage these intricacies to guarantee that their goods satisfy payers and end users alike while preserving a viable pricing structure [55].

Collaborators:

The healthcare ecosystem's stakeholders are often involved as collaborators in pharmaceutical pricing, with each one having a say in how much pharmaceuticals cost, how they're reimbursed, and how easily they may be obtained. Doctors have an institutionalized role as the key decision-maker, even though they neither pay for nor consume the pharmaceuticals they prescribe for their patients. Upon identifying an issue, doctors not only decide whether medication therapy is necessary, but also the medication and dosage to recommend. It is assumed that doctors' main goal is to provide their patients with care that complies with well recognized best practices, but it is unclear if they

are motivated to take cost into account when writing a prescription. Some key collaborators in pharmaceutical industries are pharmaceutical manufacturers, health insurance companies, pharmacy benefit managers (PBMs), government agencies, health providers, pharmacies and retailers, international collaborators, etc [56]. PBMs and insurers have the direct power to persuade doctors to recommend particular medications over others. This strategy works especially well in environments where the pay of physicians is dependent on their cost-effectiveness, such as staff health maintenance organizations. Despite the widespread misconception to the contrary, patients' financial concerns are also taken into account. According to a foundation, when prescribing medication, 53% of doctors regularly talk with patients about their out-of-pocket expenses. Research demonstrating the importance of tiered patient co-payments supports this conclusion. This is particularly noticeable in cases where patients are underfunded or without insurance.

Channels:

The word "channels" in the pharmaceutical industry usually refers to the several distribution channels that pharmaceutical products use to get to customers. These routes are essential for guaranteeing that medications and other medical supplies are supplied to patients effectively and securely [57].

Some channel players in the pharmaceutical industries are;

Pharmaceutical Companies, these are the organizations in charge of doing research, creating goods, and producing pharmaceuticals. To develop and introduce new medications into the market, they spend money on research and development (R&D).

Government Health Agencies, Standards are defined, medication applications are approved, and the safety and effectiveness of pharmaceutical products are ensured by regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and medication Administration (FDA).

Pharmacy benefit managers (PBMs), Prescription drug coverage is managed by independent companies known as pharmacy benefit managers (PBMs) for the majority of health insurance policies. Even though a lot of PBMs started out as claims processors, they have now grown into full-service organizations that create formularies, bargain with manufacturers over costs, set up pharmacy networks (lists of locations where insured patients can fill prescriptions), and provide mail-order pharmacy services. The majority of the activity in the PBM sector is concentrated in a small number of huge, multi-billion-dollar firms, despite the market being less concentrated than the drug wholesale industry. Businesses and insurers, both private and public, manage pharmacy benefits internally rather than contracting with PBMs. Sometimes self-insured employers band together to increase their negotiating leverage with manufacturers; one example of such a coalition is Rx Collaborative. These entities that carry out the PBM functions internally are also included in our references to PBMs in this chapter.

5Cs in pharmaceutical industries,

These discussion topics offer a place to start when examining the different aspects of the pharmaceutical industry's 5Cs framework. They tackle the industry's dynamic character, taking into account things like evolving consumer expectations, regulatory changes, and technology breakthroughs. The investigation of the 5Cs framework in the pharmaceutical context can also be enhanced by talks about ethical issues, healthcare access, and the role of pharmaceutical companies in addressing societal health challenges.

SWOT Analysis of Indian Pharmaceutical Pricing:

Strengths:

- **Low-Cost Manufacturing:**

Generic medication is available at reasonable rates thanks to India's competitive edge in low-cost manufacturing. This capacity enables Indian pharmaceutical businesses to manufacture and provide medications at a significantly lower cost in comparison to other nations.

- **Robust Generic Drug Market:**

One of the world's main suppliers of generic medications, India helps customers both locally and abroad by offering much lower prices for prescription drugs.

- **Government Price Controls**

In order to guarantee affordability for a wide range of important pharmaceuticals, the National Pharmaceutical Pricing Authority (NPPA) controls the cost of critical drugs in India.

- **Sturdy Supply Chain:**

India has a large pharmaceutical supply chain that makes drugs widely available and distributed throughout the nation.

Weaknesses

- **Regulatory Difficulties:**

The complicated regulatory frameworks that the Indian pharmaceutical business operates in can cause inefficiencies and sluggish reactions to changes in price.

- **Problems with Quality Control:**

There have been instances of poor quality in the Indian pharmaceutical industry, which has damaged customers' and foreign purchasers' confidence.

- **Restricted Innovation:**

Although India leads the world in the production of generics, there exists a reported deficiency in the country's ability to produce novel, high-value medications. This might have an impact on long-term price.

- **Price Control Limitations:**

Although price restrictions can guarantee affordability, they can additionally lead pharmaceutical firms to become less profitable, which may have an effect on their capacity to make R&D investments.

Opportunities:

- **Growth of the Generic Market:**

By concentrating only on generic medications, India can keep growing its market share internationally and offer more reasonably priced options to pricy branded medications.

- **Expanding Health Insurance Penetration**

Pharmaceutical businesses have a chance to provide creative pricing strategies and take advantage of an expanding customer base as health insurance becomes more widely available in India.

- **Collaborations and Partnerships:**

Indian pharmaceutical companies can collaborate with foreign businesses to reach new markets and technology, which might result in more affordable prices.

- **Innovation and Research Investment:**

Indian pharmaceutical businesses may produce high-value medications that enable more flexible pricing and global recognition by making investments in research and development.

Threats:

- **International Competition:**

India's advantage in low-cost manufacturing could become threatened if other nations strengthen their capacities for producing pharmaceuticals.

- **Regulatory Pressure:**

Tighter quality standards and more stringent laws may have an impact on pharmaceutical businesses' profit margins and pricing strategies.

- Intellectual Property Issues:

The manufacturing and cost of generic medications in India may be impacted by legal disputes pertaining to patents and intellectual property rights.

- **Global Economic Factors:**

Changes in currency exchange rates, raw material prices, and worldwide market fluctuations can all have an impact on Indian drug prices.

- **Competitive Advantage**

Reduced costs for pharmaceutical goods originating from India have played a significant role in propelling growth in global sales. How to do it is as follows:

1. Economical Manufacturing

In comparison to their Western competitors, Indian pharmaceutical businesses frequently have cheaper production costs. This is due to a number of factors, including:

- **Economies of the Scale:**

The abundance of pharmaceutical producers in India results in cost savings.

- **Reduced Labour Costs:**

In India, salaries for jobs in pharmaceutical production and research are often cheaper.

- **Reasonably priced Raw Materials:**

Having access to less expensive raw materials and active pharmaceutical ingredients (APIs) helps make production more affordable.

- **Infrastructure and technological advances:**

India's excellent technology and strong manufacturing infrastructure enable productive output.

2. Availability of Generic Medicines

India's pharmaceutical industry leads the world in producing generic medications, which are usually less expensive than branded medications. Similar therapeutic benefits are offered by generics at a significantly lower price. There are several benefits to this accessibility:

- **Decreased Healthcare Costs:**

Lower prices for generic medications save both customers' and governments' healthcare expenses, particularly in developing nations with tight budgets.

- **Enhanced Availability:**

Generics with lower prices are more widely available to a wider variety of customers, which boosts sales volumes.

- **Satisfying Global Need:**

There is a significant global need for reasonably priced pharmaceuticals. In order to address this demand and boost sales, Indian generics are essential.

3. Growing Global Markets

India has made a name for itself as a significant pharmaceutical exporter. Indian pharmaceutical businesses may expand their market share and penetrate new foreign markets by offering lower rates. This method helps to enhance sales in the following ways:

- **Competitiveness in overseas Markets:**

Indian enterprises may build a significant presence in overseas markets by offering competitively priced products.

- **Export-Oriented Development:**

Businesses in India's pharmaceutical sector export to nations in Africa, Asia, Europe, and the Americas. Increased revenues are supported by this worldwide reach.

- **Regulatory Compliance:**

Indian businesses can enter regulated markets and increase their reach by adhering to international standards (such as those set down by the FDA and EMA).

4. Getting High-Level Contracts

Indian pharmaceutical firms are able to secure significant contracts from international healthcare organisations, NGOs, and governments because of their lower costs. These agreements considerably boost revenue growth:

- **Government Acquisition:**

Indian generics are frequently chosen by governments looking to save healthcare expenses due to their affordability, which results in large-scale contracts and higher sales.

- **NGO Collaborations:**

To provide individuals in need with reasonably priced pharmaceuticals, non-governmental organisations that prioritise healthcare in underdeveloped nations frequently collaborate with Indian businesses.

- **Global Health Programmes:**

To assist their efforts, organisations such as the World Health Organisation (WHO) and the Global Fund import cheaper drugs from India.

CONCLUSION:

Price policies in the Indian pharmaceutical business are influenced by a variety of factors in an ever-changing and competitive market. With its emphasis on the intricacy of managing business operations, comprehending consumer expectations, competing in a crowded market, working with important stakeholders, and navigating regulatory situations, the 5 C framework offers a thorough grasp of the sector. Regulatory restrictions, cost structures, market rivalry, consumer price sensitivity, brand value, and global market movements all have an impact on pricing policy. Businesses in this sector need to strike a balance between these aspects in order to develop pricing strategies that support corporate goals and guarantee accessibility and legal compliance. Reduced costs for Indian pharmaceutical products provide cost-effective production, easily available generics, larger foreign markets, and the capacity to draw in big contracts, all of which lead to higher sales globally. With this approach, Indian pharmaceutical firms may contribute significantly to the improvement of medicine availability while simultaneously attaining notable worldwide sales growth. It also corresponds with the growing desire for cheap healthcare globally.

ACKNOWLEDGEMENT:

The authors are thankful to Department of Hospital Management and Hospice Studies, Jamia Millia Islamia for providing kind guidance and excellent opportunity as well as necessary facilities for the research.

CONFLICTS OF INTEREST:

The authors confirm that the content of the article has no conflict of interest.

FUNDING:

This research paper received no external funding.

REFERENCES:

1. Smith MC. Pharmaceutical marketing: strategy and cases. CRC Press; 1991 Oct 24.
2. Ahmed RR. Pharmaceutical marketing mix strategy and physician's prescription behavior. The Pharma Innovation. 2014 Sep 1;3(7, Part A):8.
3. Kalotra A. Marketing strategies of different pharmaceutical companies. Journal of Drug Delivery and Therapeutics. 2014 Mar 14;4(2):64-71.
4. Khazzaka M. Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples. BMC health services research. 2019 Dec;19:1-1.
5. Ladha Z. Marketing strategy: are consumers really influenced by brands when purchasing pharmaceutical products?. Journal of Medical Marketing. 2007 Mar;7(2):146-51.
6. Albarq AN. Pharmaceutical marketing strategies' influence on physician's prescription behavior. Archives of Pharmacy Practice. 2021;12(1-2021):7-12.
7. Yuanjia H, Ung CO, Ying B, Yitao W. Marketing strategy: The Chinese pharmaceutical market: Dynamics and a proposed investment strategy. Journal of Medical Marketing. 2007 Jan;7(1):18-24.
8. Rollins BL, Perri M. Pharmaceutical marketing. Jones & Bartlett Publishers; 2014.
9. Rader CS, Subhan Z, Lanier CD, Brooksbank R, Yankah S, Spears K. CyberRx: Emerging social media marketing strategy for pharmaceuticals. International Journal of

Pharmaceutical and Healthcare Marketing. 2014 May 27;8(2):193-225.
10. Parekh D, Kapupara P, Shah K. Digital pharmaceutical marketing: A review. Research Journal of pharmacy and technology. 2016;9(1):108-12.
11. Agrawal S, Saluja I, Kaczorowski J. A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. Academic Medicine. 2004 Nov 1;79(11):1046-51.
12. Smolynets IB, Gutyj BV, Petryshak OY, Lytvyn RI. Pharmaceutical marketing: objectives and types. Науковий вісник Львівського національного університету ветеринарної медицини та біотехнологій імені СЗ Ґжицького. 2016;18(2-4 (69)):151-4.
13. Sawad AB, Turkistani F. Pharmaceutical marketing transformation due to COVID-19 pandemic. Journal of Pharmaceutical Research International. 2021 Jun 24;33(33A):91-9.
14. Shankar V. Strategic marketing decision models for the pharmaceutical industry. Handbook of marketing decision models. 2008:469-98.
15. Rao SK. Pharmaceutical marketing in a new age. Marketing Health Services. 2002 Apr 1;22(1):6.
16. Gurau C. Pharmaceutical marketing on the internet: marketing techniques and customer profile. Journal of Consumer Marketing. 2005 Dec 1;22(7):421-8.
17. Dogramatzis D. Pharmaceutical marketing: a practical guide. CRC Press; 2015 May 6.
18. Singh J, Jayanti RK. Closing the marketing strategy-tactics gap: An institutional theory analysis of pharmaceutical value chain. InInnovation and Marketing in the Pharmaceutical Industry: Emerging Practices, Research, and Policies 2013 Oct 26 (pp. 701-735). New York, NY: Springer New York.
19. Khoso I, Ahmed RR, Ahmed J. Pricing strategies in pharmaceutical marketing. The Pharma Innovation. 2014 Sep 1;3(7, Part A):13.
20. Parker RS, Pettijohn CE. Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians. Health marketing quarterly. 2005 Apr 1;22(4):27-43.
21. Biswas K, Ferdousy UK. Influence of pharmaceutical marketing on prescription behavior of physicians: a cross-sectional study in Bangladesh. Journal of Accounting & Marketing. 2016;5(2):1-4.
22. Sergeeva NM, Reprintseva EV. MARKETING STRATEGIES OF PHARMACEUTICAL ORGANIZATION. Pharmacy & Pharmacology. 2015 Oct 15;3(5):60-3.
23. P. Moschis G, Bovell L. Marketing pharmaceutical and cosmetic products to the mature market. International Journal of Pharmaceutical and Healthcare Marketing. 2013 Nov 25;7(4):357-73.
24. Sufrin CB, Ross JS. Pharmaceutical industry marketing: Understanding its impact on women's health. Obstetrical & gynecological survey. 2008 Sep 1;63(9):585-96.
25. Nandy M, Pal B. Pharmaceutical marketing and product promotion: a paradigm shift in Indian pharmaceutical industry (IPI). Adhyayan: A Journal of Management Sciences. 2015 Dec 30;5(02):27-40.
26. Stros M, Lee N. Marketing dimensions in the prescription pharmaceutical industry: a systematic literature review. Journal of Strategic Marketing. 2015 Jun 7;23(4):318-36.

27. Bhaskarabhatla A, Bhaskarabhatla A, Mahagaonkar. Regulating Pharmaceutical Prices in India. Berlin: Springer; 2018.
28. Chaudhuri S. Pharmaceutical prices in India. InPharmaceutical prices in the 21st century 2014 Nov 28 (pp. 113-130). Cham: Springer International Publishing.
29. Khoso I, Ahmed RR, Ahmed J. Pricing strategies in pharmaceutical marketing. The Pharma Innovation. 2014 Sep 1;3(7, Part A):13.
30. Chatterjee C, Gupta S. Public entry and private prices: New evidence from Indian pharmaceutical markets. Journal of Economic Behavior & Organization. 2024 Mar 1;219:473-89.
31. Kaushik P, Tripathy S, Dureja H. Prospective of Pricing in Pharmaceutical Environment. Applied Clinical Research, Clinical Trials and Regulatory Affairs. 2014 Dec 1;1(3):151-6.
32. Roy V, Rewari S. Ambiguous drug pricing: A physician's dilemma. Indian journal of pharmacology. 1998 Nov 1;30(6):404-7.
33. Ahmad A, Khan MU, Patel I. Drug pricing policies in one of the largest drug manufacturing nations in the world: Are affordability and access a cause for concern?. Journal of research in pharmacy practice. 2015 Jan 1;4(1):1-3.
34. Dean EC. Impacts of Pharmaceutical Price Controls on Pricing, Sales, and Market-level Quality: Evidence from India. University of Pennsylvania; 2018.
35. Mondal SS, Pingali V. Competition and intellectual property policies in the Indian pharmaceutical sector. Vikalpa. 2017 Jun;42(2):61-79.
36. Lee KS, Kassab YW, Taha NA, Zainal ZA. Factors impacting pharmaceutical prices and affordability: narrative review. Pharmacy. 2020 Dec 23;9(1):1.
37. Akhtar G. Indian pharmaceutical industry: an overview. IOSR journal of Humanities and Social Science. 2013 Jul;13(3):51-66.
38. Kolte A, Mal H, Fulambrikar M, Jagtap A. Impact of price control on pharmaceutical sector with reference to India. International Journal of Intelligent Enterprise. 2021;8(1):90-104.
39. Babar ZU, Atif M. Differential pricing of pharmaceuticals: a bibliometric review of the literature. Journal of Pharmaceutical Health Services Research. 2014 Sep;5(3):149-56.
40. Tyagi S, Nauriyal DK. Firm level profitability determinants in Indian drugs and pharmaceutical industry. International Journal of Pharmaceutical and Healthcare Marketing. 2017 Sep 4;11(3):271-90.
41. Borges dos Santos MA, dos Santos Dias LL, Santos Pinto CD, da Silva RM, Osorio-de-Castro CG. Factors influencing pharmaceutical pricing-a scoping review of academic literature in health science. Journal of Pharmaceutical Policy and Practice. 2019 Dec;12:1-2.
42. Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian journal of pharmacology. 2011 Mar 1;43(2):131-6.
43. Mazumdar M, Mazumdar M. An overview of the Indian pharmaceutical sector. Performance of pharmaceutical companies in India: A critical analysis of industrial structure, firm specific resources, and emerging strategies. 2013:17-44.
44. Adwal SK, Baghel R. Price variation in different brands of anticancer drugs available in Indian pharmaceutical market: a cost analysis study. Int J Basic Clin Pharmacol. 2019 Apr;8(4):642.

45. Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi PK, Patel A, Raman K, Singhal GL, Thawani V, Tripathi S, Laing R. Prices & availability of common medicines at six sites in India using a standard methodology. Indian journal of medical research. 2007 May 1;125(5):645-54.
46. Chitra M, Kumar N. Pharmaceutical market structure in India & competition concerns. Shanlax Int J Arts Sci Humanit. 2020;8:233-41.
47. Basant R. Intellectual property rights regimes: comparison of pharma prices in India and Pakistan. Economic and Political Weekly. 2007 Sep 29:3969-77.
48. Srinivasan S. Pharma Pricing in India: A failure of the Market (s)?. 2005 Aug.
49. Danzon PM, Mulcahy AW, Towse AK. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health economics. 2015 Feb;24(2):238-52.
50. Jha R. Prices of new pharmaceuticals in india: a cross section study. Economic and Political Weekly. 2010 Mar 6:71-8.
51. Watal J. Pharmaceutical patents, prices and welfare losses: Policy options for India under the WTO TRIPS agreement. World Economy. 2000 May;23(5):733-52.
52. Scherer FM. Pricing, profits, and technological progress in the pharmaceutical industry. Journal of Economic Perspectives. 1993 Aug 1;7(3):97-115.
53. Lobo S, Bhat S. A Systematic Literature Review and Research Agenda of Share Price Movement of the Indian Pharmaceutical Industry. International Journal of Management, Technology and Social Sciences (IJMTS). 2022 Jul 14;7(2):1-27.
54. Sahu SK. Globalization, WTO, and the Indian pharmaceutical industry. Asian Affairs: An American Review. 2014 Oct 2;41(4):172-202.
55. Chatterjee B, Dash B, Shrestha B, Bhuyan NR. Current Scenarios on Regulatory Landscape of Indian Pharmaceutical Industries. Int. J. Pharm. Sci. Res. 2021;12:5642-51.
56. Bhaskarabhatla A, Chatterjee C, Anurag P, Pennings E. Mitigating regulatory impact: the case of partial price controls on metformin in India. Health policy and planning. 2017 Mar 1;32(2):194-204.
57. Bhandari PR, Bhandary A. Cost variation analysis of parenteral antibiotics in Indian pharmaceutical market. Int J Basic Clin Pharmacol. 2019 Nov;8:2535-40.

HOW TO CITE: Syed Saif Imam, Shiraz Mehdi, Factors Affecting Pharmaceutical Pricing In India, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 5, 1367-1384. https://doi.org/10.5281/zenodo.11314004